Adiposogenital dystrophy pathophysiology: Difference between revisions
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Adiposogenital dystrophy}} | {{Adiposogenital dystrophy}} | ||
{{CMG}} [[Ogechukwu Hannah Nnabude, MD]] | |||
==Overview== | ==Overview== | ||
The pathogenesis of adiposogenital dystrophy is believed to result from damage to the [[hypothalamus]] which links the [[nervous system]] to the [[endocrine system]] through the pituitary gland. | The pathogenesis of adiposogenital dystrophy is believed to result from damage to the [[hypothalamus]] which links the [[nervous system]] to the [[endocrine system]] through the pituitary gland. | ||
Revision as of 04:53, 18 August 2021
|
Adiposogenital dystrophy Microchapters |
|
Differentiating Adiposogenital dystrophy from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Adiposogenital dystrophy pathophysiology On the Web |
|
American Roentgen Ray Society Images of Adiposogenital dystrophy pathophysiology |
|
Risk calculators and risk factors for Adiposogenital dystrophy pathophysiology |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Ogechukwu Hannah Nnabude, MD
Overview
The pathogenesis of adiposogenital dystrophy is believed to result from damage to the hypothalamus which links the nervous system to the endocrine system through the pituitary gland.
Pathophysiology
The pathogenesis of adiposogenital dystrophy is believed to result from damage to the hypothalamus (arcuate nucleus and ventromedial nuclei) which links the nervous system to the endocrine system through the pituitary gland."Froelich Syndrome - NORD (National Organization for Rare Disorders)".